D. E. Shaw & Co., Inc. Nuvalent, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Nuvalent, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 156,788 shares of NUVL stock, worth $12 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
156,788
Previous 130,961
19.72%
Holding current value
$12 Million
Previous $9.29 Million
28.8%
% of portfolio
0.01%
Previous 0.01%
Shares
15 transactions
Others Institutions Holding NUVL
# of Institutions
225Shares Held
59.8MCall Options Held
191KPut Options Held
306K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.38 Billion31.57% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$404 Million18.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$347 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$232 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$138 Million0.02% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.29B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...